CrownSyn™ Drug combination Analysis Service

In the intricate landscape of oncology, our unyielding pursuit for innovative solutions against cancer has spotlighted a promising area: drug synergy. This concept has rapidly come to the forefront and is now a central and pivotal focus in cutting-edge cancer research.

Why Combine Drugs?

Cancer is not a singular disease but a myriad of ailments with complex gene and molecular interactions. While a single drug might target one specific pathway, cancer can adapt by leveraging other untargeted pathways, leading to drug resistance. This brings drug combinations into the limelight, which can offer multiple advantages:

1. Reduce Resistance: Attacking cancer from various angles reduces the chance for the disease to develop treatment resistance.
   
   
2. Increase Potency: Drugs can enhance each other's effects, resulting in a stronger suppression of the tumor.
   
   
3. Minimize Side Effects: Employing lower doses of each drug can potentially diminish adverse reactions while still retaining treatment efficacy.

Assessing Drug Synergy in In Vitro Studies

The allure of drug combinations is undeniable in the realm of medical research. Discerning which combinations truly synergize, however, has posed significant challenges. Traditionally, the synergy between drugs was explored using advanced statistical methods in standard cell lines. These in vitro studies are invaluable, providing preliminary insights into potential drug interactions before advancing to animal or human trials.

Recently, the advent of organoid technology has revolutionized these studies. Organoids offer a more complex and human-relevant model. By assessing drug combinations in these organoids, scientists can observe not just the interactions at a cellular level, but also how these drugs affect a more tissue-like structure. Incorporating organoids into drug synergy studies allows for a deeper understanding of drug interactions, potential toxicities, and effectiveness. The utilization of organoids in assessing drug combinations underscores a significant leap in in vitro studies, promising more reliable and human-relevant data in the pursuit of effective therapeutic strategies.

Breakthroughs and Challenges in In Vivo Models

Translating these findings to animal models has its own set of hurdles. Previous in vivo drug synergy studies often lacked rigorous statistical tools, which could lead to false positives. The ramifications of such inaccuracies are grave: combinations that seem promising in animal models could flounder in clinical trials.

Our publication in Cancer Research Communications heralds a transformative approach. We've introduced a method that meticulously and reliably detects drug synergy in various models. This technique is unprecedented, analyzing synergy directly from tumor volume data without making undue assumptions about tumor growth dynamics. With the advent of the invivoSyn framework, we're equipped with a potent tool to scrutinize drug synergy in vivo. Its insights, grounded in robust statistical methodologies, will play an instrumental role in shaping the trajectory of combination therapy studies. As drug synergy continues to occupy a pivotal position in therapeutic stratagems, especially in oncology, tools like invivoSyn will be indispensable. We're eager to further expand its capabilities, ensuring it aligns with an even broader array of datasets.

CrownSyn Service

Delving deeper into this promising arena, Crown Bioscience offers CrownSyn – a dedicated service for both in vitro and in vivo studies.

With the CrownSyn service, seamlessly evaluate and quantify the effects of two-drug combinations—be it synergistic, antagonistic, or additive—in both in vitro and in vivo assays. You can use data from your existing assays, or collaborate with our experts to design a study. Benefit from our diverse range of assay options and our rigorously validated in vitro and in vivo models.